Kenneth L Kehl1, Neeraj K Arora1, Deborah Schrag1, John Z Ayanian1, Steven B Clauser1, Carrie N Klabunde1, Katherine L Kahn1, Robert H Fletcher1, Nancy L Keating2. 1. Division of General Internal Medicine, Brigham and Women's Hospital, Boston, MA (KLK, NLK); Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD (NKA, SBC, CNK); Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA (DS); Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI (JZA); University of California, Los Angeles and RAND Corporation, Santa Monica, CA (KK); Department of Population Medicine (RHF) and Department of Health Care Policy (NLK, JZA), Harvard Medical School, Boston, MA. 2. Division of General Internal Medicine, Brigham and Women's Hospital, Boston, MA (KLK, NLK); Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD (NKA, SBC, CNK); Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA (DS); Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI (JZA); University of California, Los Angeles and RAND Corporation, Santa Monica, CA (KK); Department of Population Medicine (RHF) and Department of Health Care Policy (NLK, JZA), Harvard Medical School, Boston, MA. keating@hcp.med.harvard.edu.
Abstract
BACKGROUND: Clinical trials are essential to establish the effectiveness of new cancer therapies, but less than 5% of adults with cancer enroll in trials. In addition to ineligibility or lack of available trials, barriers to enrollment may include limited patient awareness about the option of participation. METHODS: We surveyed a multiregional cohort of patients with lung or colorectal cancer (or their surrogates) three to six months after diagnosis. We assessed whether respondents reported learning that clinical trial participation might be an option, and, if so, with whom they discussed trials. We used logistic regression to assess the association of patient characteristics with discussing trial participation and enrolling in trials. All statistical tests were two-sided. RESULTS: Of 7887 respondents, 1114 (14.1%) reported discussing the possibility of clinical trial participation; most learned about trials from their physicians, and 287 patients (3.6% of all patients, 25.8% of trial discussants) enrolled. Among 2173 patients who received chemotherapy for advanced (stage III/IV lung or stage IV colorectal) cancer, 25.7% discussed trials, and 7.6% (29.5% of trial discussants) enrolled. Discussions were less frequent among older patients, African American or Asian vs white patients, and those with lower incomes and more comorbidity. Enrollment was higher among patients reporting shared vs physician-driven decisions (all P < .05). CONCLUSIONS: In this population-based cohort, only 14% of patients discussed participation in clinical trials. Discussions were more frequent among advanced cancer patients but were still reported by a minority of patients. Strategies to expand access to trials and facilitate patient-provider communication about participation may accelerate development of better cancer therapeutics.
BACKGROUND: Clinical trials are essential to establish the effectiveness of new cancer therapies, but less than 5% of adults with cancer enroll in trials. In addition to ineligibility or lack of available trials, barriers to enrollment may include limited patient awareness about the option of participation. METHODS: We surveyed a multiregional cohort of patients with lung or colorectal cancer (or their surrogates) three to six months after diagnosis. We assessed whether respondents reported learning that clinical trial participation might be an option, and, if so, with whom they discussed trials. We used logistic regression to assess the association of patient characteristics with discussing trial participation and enrolling in trials. All statistical tests were two-sided. RESULTS: Of 7887 respondents, 1114 (14.1%) reported discussing the possibility of clinical trial participation; most learned about trials from their physicians, and 287 patients (3.6% of all patients, 25.8% of trial discussants) enrolled. Among 2173 patients who received chemotherapy for advanced (stage III/IV lung or stage IV colorectal) cancer, 25.7% discussed trials, and 7.6% (29.5% of trial discussants) enrolled. Discussions were less frequent among older patients, African American or Asian vs white patients, and those with lower incomes and more comorbidity. Enrollment was higher among patients reporting shared vs physician-driven decisions (all P < .05). CONCLUSIONS: In this population-based cohort, only 14% of patients discussed participation in clinical trials. Discussions were more frequent among advanced cancerpatients but were still reported by a minority of patients. Strategies to expand access to trials and facilitate patient-provider communication about participation may accelerate development of better cancer therapeutics.
Authors: P N Lara; R Higdon; N Lim; K Kwan; M Tanaka; D H Lau; T Wun; J Welborn; F J Meyers; S Christensen; R O'Donnell; C Richman; S A Scudder; J Tuscano; D R Gandara; K S Lam Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: France Légaré; Stéphane Ratté; Dawn Stacey; Jennifer Kryworuchko; Karine Gravel; Ian D Graham; Stéphane Turcotte Journal: Cochrane Database Syst Rev Date: 2010-05-12
Authors: Dawn Stacey; Carol L Bennett; Michael J Barry; Nananda F Col; Karen B Eden; Margaret Holmes-Rovner; Hilary Llewellyn-Thomas; Anne Lyddiatt; France Légaré; Richard Thomson Journal: Cochrane Database Syst Rev Date: 2011-10-05
Authors: Anneke T Schroen; Gina R Petroni; Hongkun Wang; Monika J Thielen; Robert Gray; Jacqueline Benedetti; Xiaofei F Wang; Daniel J Sargent; Donald L Wickerham; Walter Cronin; Benjamin Djulbegovic; Craig L Slingluff Journal: Clin Cancer Res Date: 2011-10-05 Impact factor: 12.531
Authors: Jennifer L Malin; Clifford Ko; John Z Ayanian; David Harrington; David R Nerenz; Katherine L Kahn; Julie Ganther-Urmie; Paul J Catalano; Alan M Zaslavsky; Robert B Wallace; Edward Guadagnoli; Neeraj K Arora; Maryse D Roudier; Patricia A Ganz Journal: Support Care Cancer Date: 2006-02-16 Impact factor: 3.603
Authors: John H Stewart; Alain G Bertoni; Jennifer L Staten; Edward A Levine; Cary P Gross Journal: Ann Surg Oncol Date: 2007-08-08 Impact factor: 5.344
Authors: Jeremy L Warner; Dmitry Dymshyts; Christian G Reich; Michael J Gurley; Harry Hochheiser; Zachary H Moldwin; Rimma Belenkaya; Andrew E Williams; Peter C Yang Journal: J Biomed Inform Date: 2019-06-22 Impact factor: 6.317
Authors: Kenneth L Kehl; Mary Beth Landrum; Katherine L Kahn; Stacy W Gray; Aileen B Chen; Nancy L Keating Journal: J Oncol Pract Date: 2015-04-28 Impact factor: 3.840
Authors: Kenneth L Kehl; Cheryl P Fullmer; Siqing Fu; Goldy C George; Kenneth R Hess; Filip Janku; Daniel D Karp; Shumei Kato; Cynthia K Kizer; Razelle Kurzrock; Aung Naing; Shubham Pant; Sarina A Piha-Paul; Vivek Subbiah; Apostolia M Tsimberidou; David S Hong Journal: Clin Cancer Res Date: 2017-07-20 Impact factor: 12.531
Authors: Neal J Meropol; Yu-Ning Wong; Terrance Albrecht; Sharon Manne; Suzanne M Miller; Anne Lederman Flamm; Al Bowen Benson; Joanne Buzaglo; Michael Collins; Brian Egleston; Linda Fleisher; Michael Katz; Tyler G Kinzy; Tasnuva M Liu; Seunghee Margevicius; Dawn M Miller; David Poole; Nancy Roach; Eric Ross; Mark D Schluchter Journal: J Clin Oncol Date: 2015-12-23 Impact factor: 44.544